Tanke Biosciences Corp Income Statement
TNBI|3 years of annual SEC 10-K data (FY2010-FY2012)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Tanke Biosciences Corp reported $29M in revenue and $210,247 in net loss for FY2012. Revenue has grown at a 19.2% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2012 | FY2011 | FY2010 |
|---|---|---|---|
| Revenue | $28.6M | $23.8M | $20.1M |
| Cost of Revenue | $18.6M | $15.1M | $12.7M |
| Gross Profit | $9.9M | $8.8M | $7.4M |
| SG&A Expense | $2.6M | $4.5M | $834.8K |
| R&D Expense | $290.7K | $246.0K | - |
| Operating Income | $4.5M | $1.7M | $4.4M |
| Interest Expense | $1.4M | $1.4M | $100.3K |
| Income Tax | $831.6K | $681.3K | $582.5K |
| Net Income | -$210.2K | -$3.1M | $2.7M |
| EPS (Basic) | - | $0.34 | $0.34 |
| EPS (Diluted) | -$0.02 | $0.34 | $0.34 |
| Shares Outstanding | 13.3M | 10.8M | 10.8M |
| Gross Margin | 34.8% | 36.8% | 36.8% |
| Operating Margin | 15.9% | 7.3% | 21.8% |
| Profit Margin | -0.7% | -13.2% | 13.6% |